Sympathetic renal denervation: Hypertension beyond SYMPLICITY

Cardiovascular Revascularization Medicine

Volumn 14, Issue 4, 2013, Pages 229-235

  Barbash, Israel M ^a   Waksman, Ron ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

Brachytherapy; Hypertension; Radiofrequency; Renal denervation; Ultrasound

Indexed keywords

C PEPTIDE; GLUCOSE; GUANETHIDINE; HEMOGLOBIN A1C; NARCOTIC AGENT; NEUROTOXIN; NORADRENALIN; VINCRISTINE;

BETA RADIATION; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BRACHYTHERAPY; CLINICAL EVALUATION; DEVICE SAFETY; DIASTOLIC DYSFUNCTION; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; INSULIN SENSITIVITY; KIDNEY ANGIOGRAPHY; KIDNEY DENERVATION; KIDNEY NERVE; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RADIOFREQUENCY; RESISTANT HYPERTENSION; REVIEW; SLEEP DISORDERED BREATHING; SYMPATHETIC NERVE; THERMOGENESIS; ULTRASOUND; VASCULAR ACCESS;

BRACHYTHERAPY; HYPERTENSION; RADIOFREQUENCY; RENAL DENERVATION; ULTRASOUND;

BLOOD PRESSURE; BRACHYTHERAPY; HUMANS; HYPERTENSION; KIDNEY; RENAL ARTERY; SYMPATHECTOMY;

EID: 84881346367     PISSN: 15538389     EISSN: 18780938     Source Type: Journal    
DOI: 10.1016/j.carrev.2013.02.004     Document Type: Review

References (33)

1. Vital signs: awareness and treatment of uncontrolled hypertension among adults - United States, 2003-2010. MMWR Morb Mortal Wkly Rep 2012, 61:703-709.
2. Egan B.M., Zhao Y., Axon R.N., Brzezinski W.A., Ferdinand K.C. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation 2011, 124:1046-1058.
3. Persell S.D. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension 2011, 57:1076-1080.
4. Calhoun D.A., Jones D., Textor S., Goff D.C., Murphy T.P., Toto R.D., et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008, 117:e510-e526.
5. Prevalence, awareness, treatment and control of hypertension in 600 urban and rural communities from 17 high, middle and low income countries: results from the PURE (Prospective Urban Rural Epidemiology) ESC Congress (Munich, Germany). August 2012.
6. Esler M.D., Krum H., Sobotka P.A., Schlaich M.P., Schmieder R.E., Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010, 376:1903-1909.
7. Krum H., Schlaich M., Whitbourn R., Sobotka P.A., Sadowski J., Bartus K., et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009, 373:1275-1281.
8. Global renal denervation device market 2011-2015. http://www.reportstack.com/product/70535/global-renal-denervation-device-market-2011-2015.html.
9. Esler M. The sympathetic system and hypertension. Am J Hypertens 2000, 13(6 Pt 2):99S-105S.
10. Wyss J.M., Carlson S.H. The role of the central nervous system in hypertension. Curr Hypertens Rep 1999, 1:246-253.
11. Campese V.M., Kogosov E. Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension 1995, 25(4 Pt 2):878-882.
12. Smithwick R.H. Hypertensive vascular disease; results of and indications for splanchnicectomy. J Chronic Dis 1955, 1:477-496.
13. Allen T.R. Current status of lumbar sympathectomy. Am Surg 1976, 42:89-91.
14. Use of gamma radiation for treatment of renal artery in-stent restenosis. Cardiovasc Radiat Med 2001, 2:197-198.
15. Costantini C.O., Lansky A.J., Mintz G.S., Shirai K., Dangas G., Mehran R., et al. Intravascular brachytherapy for native coronary ostial in-stent restenotic lesions. J Am Coll Cardiol 2003, 41:1725-1731.
16. Dilcher C., Satler L.F., Pichard A.D., Kent K.M., Porrazzo M., Chan R., et al. Intracoronary radiation therapy using a novel beta emitter for in-stent restenosis tungsten WRIST. Cardiovasc Revasc Med 2005, 6:52-57.
17. Kuchulakanti P., Torguson R., Canos D., Satler L.F., Suddath W., Chan R., et al. Optimizing dosimetry with high-dose intracoronary gamma radiation (21Gy) for patients with diffuse in-stent restenosis. Cardiovasc Revasc Med 2005, 6:108-112.
18. Waksman R., Ajani A.E., White R.L., Chan R., Bass B., Pichard A.D., et al. Five-year follow-up after intracoronary gamma radiation therapy for in-stent restenosis. Circulation 2004, 109:340-344.
19. Waksman R., Cheneau E., Ajani A.E., White R.L., Pinnow E., Torguson R., et al. Intracoronary radiation therapy improves the clinical and angiographic outcomes of diffuse in-stent restenotic lesions: results of the Washington Radiation for In-Stent Restenosis Trial for Long Lesions (Long WRIST) studies. Circulation 2003, 107:1744-1749.
20. Guerra P.G., Talajic M., Thibault B., Dubuc M., Roy D., Macle L., et al. Beta-radiation for the creation of linear lesions in the canine atrium. Circulation 2004, 110:911-914.
21. Silva A., Wang Q., Wang M., Ravula S.K., Glass J.D. Evidence for direct axonal toxicity in vincristine neuropathy. J Peripher Nerv Syst 2006, 11:211-216.
22. Koistinaho J., Hervonen A. Neuronal degeneration and lipopigment formation in rat sympathetic ganglion after treatment with high-dose guanethidine. Neurosci Lett 1989, 102:349-354.
23. Rippy M.K., Zarins D., Barman N.C., Wu A., Duncan K.L., Zarins C.K. Catheter-based renal sympathetic denervation: chronic preclinical evidence for renal artery safety. Clin Res Cardiol 2011, 100:1095-1101.
24. Stefanadis C., Toutouzas K., Synetos A., Tsioufis C., Karanasos A., Agrogiannis G., et al. Chemical denervation of the renal artery by vincristine in swine. A new catheter based technique. Int J Cardiol 2012, [Epub ahead of print].
25. Owens CD. Periadventitial renal artery delivery of guanethidine monosulfate attenuates renal nerve function: preclinical experience and implication for resistant hypertension. TCT 2011, San Francisco, CA 2011.
26. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24months. Hypertension 2011, 57:911-917.
27. Papademetriou V., Worthley S.G., Tsioufis C., Worthley M., Chew D., Sinhal A., et al. Catheter-based renal denervation for the treatment of patients with drug-resistant hypertension: EnligHTN I: three-month data of a first in man study using a multi-electrode radiofrequency ablation catheter. Circulation 2012, 126(A19523).
28. Brandt M.C., Mahfoud F., Reda S., Schirmer S.H., Erdmann E., Bohm M., et al. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol 2012, 59:901-909.
29. Mahfoud F., Schlaich M., Kindermann I., Ukena C., Cremers B., Brandt M.C., et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation 2011, 123:1940-1946.
30. Witkowski A., Prejbisz A., Florczak E., Kadziela J., Sliwinski P., Bielen P., et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension 2011, 58:559-565.
31. Pokushalov E., Romanov A., Corbucci G., Artyomenko S., Baranova V., Turov A., et al. A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension. J Am Coll Cardiol 2012, 60:1163-1170.
32. Geisler B.P., Egan B.M., Cohen J.T., Garner A.M., Akehurst R.L., Esler M.D., et al. Cost-effectiveness and clinical effectiveness of catheter-based renal denervation for resistant hypertension. J Am Coll Cardiol 2012, [Online before print].
33. Bergmann M.W., Kleinbongardt A., Wiese A., Kuck K.H. Results from the ALSTER hypertension registry: reduction of HTN drugs following renal denervation. EuroIntervention 2012, 80(Suppl N). Abstract 445.